Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 8/20 | 0.50 |
| ▸ | HTT | P42858 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | NOS1 | P29475 | 2/20 | 0.45 |
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | PLK1 | P53350 | 1/20 | 0.44 |
| ▸ | SLC11A2 | P49281 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22275816 | 0.98 | IDO1 (0.51) | IDO1HTTSMN1; SMN2LMNATAAR1 | |
| Bromide SCHEMBL4437988 | 0.83 | IDO1 (0.57) | IDO1HTTSMN1; SMN2LMNATAAR1 | |
| Bromide SCHEMBL2887381 | 0.82 | LMNA (0.51) | IDO1HTTSMN1; SMN2LMNATAAR1 | |
| Bromide SCHEMBL4961580 | 0.81 | IDO1 (0.58) | IDO1HTTSMN1; SMN2LMNATAAR1 | |
| SCHEMBL3687681 | 0.81 | IDO1 (0.59) | IDO1HTTSMN1; SMN2LMNATAAR1 | |
| SCHEMBL10395545 | 0.81 | LMNA (0.52) | IDO1HTTSMN1; SMN2LMNATAAR1 | |
| SCHEMBL28653909 | 0.80 | IDO1 (0.57) | IDO1HTTSMN1; SMN2LMNATAAR1 | |
| Hydrochloric Acid SCHEMBL10742194 | 0.79 | IDO1 (0.53) | IDO1HTTSMN1; SMN2LMNATAAR1 | |
| Hydrochloric Acid SCHEMBL30130145 | 0.79 | IDO1 (0.53) | IDO1HTTSMN1; SMN2LMNATAAR1 | |
| Bromide SCHEMBL30130157 | 0.79 | IDO1 (0.50) | IDO1HTTSMN1; SMN2LMNATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092020-A1 | IDO/TDO Inhibitor | GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2025-03-20 | — | — | US | disclosed |
| US-12209079-B2 | IDO/TDO inhibitor | GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2025-01-28 | — | — | US | disclosed |
| US-20220380305-A1 | IDO/TDO Inhibitor | CANBAS CO., LTD. | 2022-12-01 | — | — | US | disclosed |
| US-20200239452-A1 | IDO/TDO Inhibitor | CANBAS CO., LTD. (JP) | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209079-B2 | IDO/TDO inhibitor | IDO1, IDO2, TDO2 | IDO1 1/4885HTT 71/4885SMN1; SMN2 1967/4885 |
| US-20200239452-A1 | IDO/TDO Inhibitor | IDO1, IDO2, TDO2 | IDO1 1/4885HTT 71/4885SMN1; SMN2 1967/4885 |
| US-20250092020-A1 | IDO/TDO Inhibitor | IDO1, IDO2, TDO2 | IDO1 1/4885HTT 71/4885SMN1; SMN2 1967/4885 |
| US-20220380305-A1 | IDO/TDO Inhibitor | IDO1, IDO2, TDO2 | IDO1 1/4885HTT 100/4885SMN1; SMN2 2109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.